2015 Publications

Top Publications

Kaukonen, K., Bailey, M.J., Pilcher, D.V., Cooper, D.J., Bellomo, R., 2015, Systemic inflammatory response syndrome criteria in defining severe sepsis, New England Journal Of Medicine [P], vol 372, issue 17, pp. 1629-1638.

Young, P.J., Saxena, M.K., Bellomo, R., Freebairn, R.C., Hammond, N.E., Van Haren, F.M.P., Holliday, M., Henderson, S.J., Mackle, D., McArthur, C., McGuinness, S.P., Myburgh, J.A., Weatherall, M.W., Webb, S.A.R., Beasley, R.W., 2015, Acetaminophen for fever in critically iII patients with suspected infection, New England Journal of Medicine [P], vol 373, issue 23, pp. 2215-2224.

Leaute-Labreze, C., Hoeger, P.H., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., Phillips, R.J., Caceres, H., Lopez Gutierrez, J., Ballona Chambergo, R.A., Friedlander, S.F., Powell, J., Perek, D., Metz, B.J., Barbarot, S., Maruani, A., Szalai, Z.Z., Krol, A.L., Boccara, O., Foelster-Holst, R., Febrer Bosch, M.I., Su, J.C., Buckova, H., Torrelo, A., Cambazard, F., Grantzow, R., Wargon, O., Wyrzykowski, D., Roessler, J., Bernabeu-Wittel, J., Valencia-Herrera, A.M., Przewratil, P., Glick, S.A., Pope, E., Birchall, N.M., Benjamin, L., Mancini, A.J., Vabres, P., Souteyrand, P., Frieden, I.J., Berul, C.I., Mehta, C.R., Prey, S., Boralevi, F., Morgan, C.C., Heritier, S.R., Delarue, A., Voisard, J., 2015, A randomized, controlled trial of oral propranolol in infantile hemangioma, New England Journal Of Medicine [P], vol 372, issue 8, pp. 735-746.

Murray C.J.L., Barber R.M., Foreman K.J., Ozgoren A.A., Abd-Allah F., Abera S.F., Aboyans V., Abraham J.P., Abubakar I., Abu-Raddad L.J., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition. 2015. The Lancet 386 (10009) 2145-2191.

Ilic D, Dahm P. Prostate cancer screening in Europe. The Lancet 2015;385:1506.

Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015 May 23; 385(9982): 2107-17. Review.

GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015 Aug 27. /S0140-6736(15)61340.

Ashley, D., Thomas, D., Gore, L., Carter, R., Zalcberg, J.R., Otmar, R. and Savulescu, J., 2015. Accepting risk in the acceleration of drug development for rare cancers. The Lancet Oncology, 16(4), pp.e190-e194.

Vos T., Barber R.M., Bell B., Bertozzi-Villa A., Biryukov S., Bolliger I., Charlson F., Davis A., Degenhardt L., Dicker D., Duan L., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. 2015, The Lancet 386 (9995) 743-800.

Forouzanfar M.H., Alexander L., Anderson H.R., Bachman V.F., Biryukov S., Brauer M., Burnett R., Casey D., Coates M.M.,et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. 2015, The Lancet 386 (10010) 2287-2323.

Ashley, D., Thomas, D., Gore, L., Carter, R., Zalcberg, J.R., Otmar, R. and Savulescu, J., 2015. Accepting risk in the acceleration of drug development for rare cancers. The Lancet Oncology, 16(4), pp.e190-e194.

All Publications 2015